NEWS CENTER

Initial Release of caIMR's Clinical Application Potential! RainMed’s caIMR Empowered the development of clinical treatment strategies, adding strong evidence for the concept of "intervention without implantation" for STEMI patients

  • Categories:News Center
  • Author:
  • Origin:
  • Time of issue:2022-08-12 14:33
  • Views:

(Summary description)Recently, Professor Zhirong Wang's team from The Affiliated Hospital of Xuzhou Medical University published a paper in SCI journal titled "Computational Pressure-Fluid Dynamics Applied to Index of Microcirculatory Resistance, Predicting the Prognosis of Drug-Coated Balloons Compared With Drug-Coated Balloons Compared With Drug-Eluting Stents in STEMI Patients". The paper indicates that RainMed’s caIMR can independently predict the likelihood of cardiac death or readmission due to heart failure in STEMI patients. At the same time, caIMR confirmed that the effect of drug-coated balloon (DCB) therapy is not inferior to drug-eluting stent (DES) in the diagnosis and treatment of STEMI by accurately diagnosing the damage of coronary microcirculation. It has added strong clinical evidence for the advanced diagnosis and treatment concept of "intervention without implantation" in STEMI patients and assisted clinical development of better interventional diagnosis and treatment strategy.

Initial Release of caIMR's Clinical Application Potential! RainMed’s caIMR Empowered the development of clinical treatment strategies, adding strong evidence for the concept of "intervention without implantation" for STEMI patients

(Summary description)Recently, Professor Zhirong Wang's team from The Affiliated Hospital of Xuzhou Medical University published a paper in SCI journal titled "Computational Pressure-Fluid Dynamics Applied to Index of Microcirculatory Resistance, Predicting the Prognosis of Drug-Coated Balloons Compared With Drug-Coated Balloons Compared With Drug-Eluting Stents in STEMI Patients". The paper indicates that RainMed’s caIMR can independently predict the likelihood of cardiac death or readmission due to heart failure in STEMI patients. At the same time, caIMR confirmed that the effect of drug-coated balloon (DCB) therapy is not inferior to drug-eluting stent (DES) in the diagnosis and treatment of STEMI by accurately diagnosing the damage of coronary microcirculation. It has added strong clinical evidence for the advanced diagnosis and treatment concept of "intervention without implantation" in STEMI patients and assisted clinical development of better interventional diagnosis and treatment strategy.

  • Categories:News Center
  • Author:
  • Origin:
  • Time of issue:2022-08-12 14:33
  • Views:
Information

Recently, Professor Zhirong Wang's team from The Affiliated Hospital of Xuzhou Medical University published a paper in SCI journal titled "Computational Pressure-Fluid Dynamics Applied to Index of Microcirculatory Resistance, Predicting the Prognosis of Drug-Coated Balloons Compared With Drug-Coated Balloons Compared With Drug-Eluting Stents in STEMI Patients". The paper indicates that RainMed’s caIMR can independently predict the likelihood of cardiac death or readmission due to heart failure in STEMI patients. At the same time, caIMR confirmed that the effect of drug-coated balloon (DCB) therapy is not inferior to drug-eluting stent (DES) in the diagnosis and treatment of STEMI by accurately diagnosing the damage of coronary microcirculation. It has added strong clinical evidence for the advanced diagnosis and treatment concept of "intervention without implantation" in STEMI patients and assisted clinical development of better interventional diagnosis and treatment strategy.

 

 

IMR is a good indicator to reflect coronary microcirculation and predict the prognosis of STEMI. It is a safe, convenient and efficient choice which requires no pressure guide wire, hyperemic agents, or saline injection. On EuroPCR 2022, academician Junbo Ge announced the results of the pre-marketing clinical research of caIMR system, pointing out that the accuracy of online and offline measurement was as high as 93.81% and 94.69% respectively. Compared with guide wire-based IMR, it has high accuracy, sensitivity and speciality.

 

 

This study retrospectively analyzed 213 STEMI patients who underwent PPCI. caIMR values and the incidence of major adverse cardiovascular events were compared between DCB and DES groups after PSM (propensity partitioning matching) was used to reduce bias and confounding variables. The results showed that:

 

1. The immediate revascularization effect of DCB or DES in STEMI patients is similar, and the long-term prognosis of DCB group is not worse than that of DES group. caIMR was calculated after PPCI in STEMI patients, and it was found that the assessment of microvascular injury was similar between DCB and DES groups, but the incidence of adverse cardiovascular events was higher in DES group than in DCB group after 1 year of follow-up.

 

2. caIMR can be used as an independent predictor of cardiac death rate and readmission rate due to heart failure. Using caIMR=40U as the cutoff value, caIMR40U is the reference range of normal microcirculation in STEMI patients, and caIMR > 40U is the indication of microcirculation injury in STEMI patients. The incidence of adverse cardiovascular events in the caIMR > 40U group was higher than that in the caIMR40U group, and it is statistically significant.

 

 

After stent implantation in STEMI patients, long-term antiplatelet therapy may cause in-stent restenosis, stent thrombosis and bleeding. In response, the concept of "non-implantation intervention" was proposed in Europe (De Luca et al., 2008; Neumann et al., 2019; Her et al., 2021), advocating the use of DCB for intervention. In this study, caIMR system enabled the physicians to map out the clinical treatment strategy for the first time. As an important measurement of microvascular injury, it is able to evaluate the prognostic effect of DCB and DES, and release its clinical application potential.

 

At present, there is no clinical quantitative measurement product that can easily and effectively diagnose coronary microcirculation. In April this year, caIMR system successfully entered the National Medical Products Administration innovative medical devices special approval channel, pressed the key to accelerate the commercialization process. It is expected that the caIMR system will be commercialized in China at the end of this year, opening the blue ocean market of more than 10 billion yuan. As the world's first non-invasive IMR system, the large-scale clinical application of caIMR system will open a new era of comprehensive assessment of myocardial ischemia and bring epoch-making significance to promote the development of coronary precision medicine.

 

In the future, caIMR system will combine with caFFR system, which is an important part of functional diagnosis module and will be integrated on FlashBot vascular interventional surgery robot. It will build an integrated solution of cathlab diagnosis and treatment, and contribute Chinese wisdom to promoting precise coronary diagnosis and treatment.

CONTACT US

0512-62622215

Address: Building 31, Northeast District, Nano City, No. 99 Jinji Lake Avenue, Suzhou industrial park

这是描述信息

WeChat public account

这是描述信息

Recruitment QR Code

Page Copyright© 2021- Suzhou Rainmed Medical Technology Co., Ltd.  苏公网安备32059002003601号  (苏)-非经营性-2021-0149